Atea Pharmaceuticals: Backing a Phase-3 HCV Underdog Ahead of Upcoming Clinical Catalysts
Atea (AVIR) is a clinical-stage antiviral developer trading at a modest market cap with Phase 3 HCV programs advancing and an HEV program entering first-in-human studies. Given recent drug-drug interaction data and an improving clinical narrative, I favor a long trade into upcoming catalysts with a defined entry, stop and target — while acknowledgi…